BREAKING
Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 7 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 8 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 9 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 3 days ago Zoom Communications Q4 2025 Earnings Results 4 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 4 days ago Synopsys Q1 2026 Earnings Results 4 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 4 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 4 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 5 days ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 7 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 8 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 9 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 3 days ago Zoom Communications Q4 2025 Earnings Results 4 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 4 days ago Synopsys Q1 2026 Earnings Results 4 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 4 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 4 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 5 days ago
ADVERTISEMENT
Market News

Acasti Pharma (ACST): Q3 2020 Earnings Snapshot

— Acasti Pharma Inc. (NASDAQ: ACST) reported Q3 2020 net loss of CAD15.7 million, or CAD0.18 per share, compared to net loss of CAD4.6 million, or CAD0.07 per share, last year. — Loss from operating activities was CAD7.9 million compared to a loss of CAD10.7 million last year. — R&D expenses before depreciation, amortization and […]

$ACST February 14, 2020 1 min read
NYSE
$ACST · Earnings

— Acasti Pharma Inc. (NASDAQ: ACST) reported Q3 2020 net loss of CAD15.7 million, or CAD0.18 per share, compared to net loss of CAD4.6 million, or CAD0.07 per share, last year. — Loss from operating activities was CAD7.9 million compared to a loss of CAD10.7 million last year. — R&D expenses before depreciation, amortization and […]

· February 14, 2020

— Acasti Pharma Inc. (NASDAQ: ACST) reported Q3 2020 net loss of CAD15.7 million, or CAD0.18 per share, compared to net loss of CAD4.6 million, or CAD0.07 per share, last year.

— Loss from operating activities was CAD7.9 million
compared to a loss of CAD10.7 million last year.

— R&D expenses before depreciation, amortization and stock-based compensation expenses were CAD4.2 million compared to CAD8.8 million last year.

— General and administrative expenses before stock-based compensation expenses were CAD1.6 million versus CAD0.76 million last year.

— Sales and marketing expenses before stock-based compensation expenses were CAD0.74 million compared to CAD0.13 million last year.

ADVERTISEMENT

— Cash and cash equivalents and
marketable securities totaled CAD25.7 million as of December 31, 2019.

— ACST shares gained 0.69% immediately following the announcement.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

ADVERTISEMENT